



## **SightGlass Vision Expands Canada Team to Elevate DOT™ Spectacle Lens Awareness and Education**

*Business Development Managers Will Help Eye Care Professionals Nationwide Understand the Power of Contrast Management for Childhood Myopia*

**DALLAS, February 11, 2026**—SightGlass Vision has launched a new Canada-based team dedicated to expanding awareness and education about DOT™ spectacle lenses among Eye Care Professionals in the country. DOT lenses are the only single-vision spectacle lens option that provides myopia control through contrast management while preserving excellent visual acuity.<sup>[1],[2]</sup> This team of Business Development Managers is now supporting SightGlass Vision and its partners to help Canadian practices understand, adopt, and confidently offer this evidence-based technology to slow myopia progression in children.

In Canada, MiSight® spectacle lenses powered by Diffusion Optics Technology™ are available from CooperVision. They correct vision and slow the worsening of myopia.<sup>[3]</sup> Research has demonstrated that DOT lenses slow average myopia progression by up to 75% after 12 months of wear across diverse populations of children.<sup>[4],[5].\*</sup>

SightGlass Vision's new Business Development Managers, Sharon Koch and Gemma Gibb, bring a wealth of optical industry experience to their roles supporting optometrists and opticians initially in Ontario and British Columbia. Koch, based in Toronto, has over 13 years of experience as an optometric assistant and more than 25 years in client relationship management, with experience spanning Shamir Canada, Eye Recommend, and independent optometry practice. Gibb, based in Vancouver, has built her expertise over nearly a decade in the optical sector, holding business development and account management roles with Nikon Optical Canada and The Optical Group.

“Contrast management is still relatively new to many Eye Care Professionals in Canada, so there’s a real opportunity for education,” said Koch. “Once Eye Care Professionals understand how this approach supports myopia control, DOT lenses naturally become a strong addition to their myopia toolkit—providing a new, effective option for children as young as six.”<sup>[5],[6],[7]</sup>

“Many of the practices I meet with are already engaged with myopia management, so there’s a strong foundation of interest,” said Gibb. “As Eye Care Professionals become aware of how contrast management works and how the lenses are as easy to adapt to as regular single vision lenses,<sup>[8]</sup> they’re eager to learn more. I believe DOT lenses are on a clear path toward becoming a mainstream myopia control option as momentum grows across the country, as we’ve seen in China.”

DOT lenses are designed to slow myopia progression by mimicking more natural contrast.<sup>3,5</sup> They do this by integrating thousands of elements that softly scatter light before it hits the retina.<sup>4</sup>

In addition to Canada, SightGlass Vision’s DOT lenses have made their commercial debut in China, Israel, Spain, and the U.K., with over 1.5 million children having already worn the lenses.<sup>†,‡</sup> Founded in 2016, the company now operates as a joint venture of CooperVision, Inc. and Essilor International.

For more information, visit [SightGlassVision.com](https://SightGlassVision.com)

###

### **About SightGlass Vision**

SightGlass Vision develops innovative technologies and science-based treatments to address the global myopia epidemic, backed by novel and comprehensive research. Its unique Diffusion Optics Technology™ is based on ground-breaking discoveries surrounding myopia progression. Spectacle lenses using its patent-protected approach incorporate thousands of light-scattering elements designed to mimic more natural contrast on the retina—a method intended to reduce myopia progression in children. The treatment has completed the three years pivotal multisite clinical study. Founded in 2016, the company now operates as a joint venture of CooperVision, Inc. and Essilor International to accelerate commercialization opportunities and expand the myopia management category worldwide.

**\* Patient population aged 6–10 years (CYPRESS) and 6–13 years (CATHAY). Prescribed DOT lens wear time was 10 hours per day.**

† *This figure is based on sales data and reflects global usage across multiple regions.*

‡ *SightGlass Vision™ Diffusion Optics Technology™ spectacle lenses are not available for sale in the United States.*

### **Media Contact**

Carson Daniels, Senior Counselor

McDougall Communications for SightGlass Vision

+1-315-427-6394 or [carson@mcdougallpr.com](mailto:carson@mcdougallpr.com)

---

[1] Wolffsohn SJ et al. Visual impact of diffusion optic technology lenses for myopia control. *Ophthalmic Physiol Opt* 2024; 44: 1398–1406.

[2] SGV data on file, 2023.

[3] Laughton D, et al. Control of myopia using diffusion optics spectacle lenses: 4-year results of a multicentre randomised controlled, efficacy and safety study (CYPRESS): *BMJ Open Ophthalmology* 2024;9:e001790.

[4] Rappon et al. Control of myopia using diffusion optics spectacle lenses: 12-month results of a randomised controlled, efficacy and safety study. *Br J Ophthalmol.* 2023;107:1709-1715.

[5] Laughton et al. Control of myopia using contrast modulation spectacle lenses in a Chinese population: 12-month results. *Invest. Ophthalmol. Vis. Sci.* 2025;66(8):2815.

[6] Rappon J et al. Two-year effectiveness of a novel myopia management spectacle lens with full-time wearers. *Invest. Ophthalmol. Vis. Sci.* 2022;63(7):408.

[7] Laughton D et al. Control of Myopia using Diffusion Optics Technology spectacle lenses: 4-year results. *AAOptom conference 2023 presentation.*

[8] McParland et al. Children adapt well to Diffusion Optics Technology™ (DOT™) spectacle lenses. Presented at NCC 2024